MedTrace Logo

Phase III Study on HMPL-523 for Treatment of ITP

NCT05029635 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 272

Last updated 2026-05-04

No results posted yet for this study

Summary

The purpose of this study is to determine whether HMPL-523 (sovleplenib) is safe and effective in the treatment of chronic Immune Thrombocytopenic Purpura (ITP).

Conditions

  • Primary Immune Thrombocytopenia (ITP)

Interventions

DRUG

HMPL-523

HMPL-523(300mg PO QD)

DRUG

Placebo

Placebo(300mg PO QD)

Sponsors & Collaborators

  • Hutchmed

    lead INDUSTRY

Principal Investigators

  • Renchi Yang, professor · offices director

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-27
Primary Completion
2025-05-16
Completion
2025-09-18

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05029635 on ClinicalTrials.gov